|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 653.56 USD | -3.20% |
|
-1.95% | -15.60% |
| 08:52pm | What Bundibugyo Ebola vaccines and treatments are under development | RE |
| 07-22 | Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $750 From $785 | MT |
| Market Cap | 68.69B 60.19B 55.88B 51.35B 96.75B 6,629B 98.18B 666B 261B 3,243B 258B 252B 11,204B | P/E 2026 * |
17.8x | P/E 2027 * | 14.2x |
|---|---|---|---|---|---|
| Enterprise Value | 60.87B 53.33B 49.51B 45.5B 85.73B 5,874B 87B 590B 231B 2,874B 229B 224B 9,929B | EV / Sales 2026 * |
3.83x | EV / Sales 2027 * | 3.3x |
| Free-Float |
72.33% | Yield 2026 * |
0.58% | Yield 2027 * | 0.66% |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | -3.20% | ||
| 1 week | -1.95% | ||
| Current month | +4.48% | ||
| 1 month | +6.36% | ||
| 3 months | -12.74% | ||
| 6 months | -13.77% | ||
| Current year | -15.60% |
| 1 week | 648.9 |  | 691.13 |
| 1 month | 607.92 | | 691.13 |
| Current year | 591.52 | | 821.11 |
| 1 year | 541 | | 821.11 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Michael Brown
BRD | Director/Board Member | 85 | 01/06/1991 |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 2/7/26 | Sell | Director | -200 | 0.0002% | ||
| 1/5/26 | Sell | Director | -100 | 0.0001% | ||
| 1/4/26 | Sell | Director | 100 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.20% | -1.95% | +16.14% | -10.41% | 68.69B | |
| -0.25% | +3.22% | +41.00% | +198.82% | 52.97B | |
| -1.65% | +37.20% | +37.20% | +37.20% | 43.61B | |
| -2.83% | -4.08% | -53.81% | -55.84% | 40.75B | |
| -1.22% | +1.72% | +56.93% | -27.57% | 29.99B | |
| -1.63% | -14.23% | +78.93% | -52.39% | 23.67B | |
| -0.61% | +1.52% | +69.58% | +84.12% | 23.45B | |
| +0.11% | +2.44% | +4.06% | +181.25% | 20.46B | |
| -0.39% | +1.58% | +71.18% | +126.61% | 16.66B | |
| -0.11% | -0.39% | +79.89% | +147.70% | 16.16B | |
| Average | -1.17% | +0.41% | +40.11% | +62.95% | 33.64B | |
| Weighted average by Cap. | -1.53% | +1.07% | +31.15% | +51.35% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 15.88B 13.91B 12.92B 11.87B 22.36B 1,532B 22.69B 154B 60.22B 750B 59.61B 58.32B 2,590B | 17.65B 15.46B 14.35B 13.19B 24.86B 1,703B 25.22B 171B 66.93B 833B 66.24B 64.82B 2,878B |
| Net income | 3.98B 3.48B 3.23B 2.97B 5.6B 384B 5.68B 38.53B 15.08B 188B 14.93B 14.61B 649B | 5.03B 4.4B 4.09B 3.76B 7.08B 485B 7.18B 48.7B 19.06B 237B 18.86B 18.46B 820B |
| Net Debt | -7.82B -6.85B -6.36B -5.85B -11.02B -755B -11.18B -75.8B -29.67B -369B -29.37B -28.73B -1,276B | -10.51B -9.21B -8.55B -7.86B -14.81B -1,014B -15.03B -102B -39.87B -496B -39.46B -38.61B -1,715B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/07/26 | US$651.44 | -3.52% | 326,591 |
| 21/07/26 | US$675.19 | +0.45% | 529,783 |
| 20/07/26 | US$672.15 | -0.67% | 624,791 |
| 17/07/26 | US$676.69 | -0.33% | 648,400 |
| 16/07/26 | US$678.94 | +2.18% | 730,245 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition